SeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business Updates

Revenue surged 247%, but losses widened and cash burn remains high.

What the company is saying

SeaStar Medical frames its narrative around rapid commercial traction for QUELIMMUNE therapy in ultra-rare pediatric AKI, highlighting a 247% increase in net revenue to $635 thousand for Q3 2026. CEO Eric Schlorff emphasizes statistically significant survival benefits in treated patients, referencing real-world data and recent medical conference presentations. The company underscores regulatory progress, including FDA fulfillment of post-approval requirements, submission of the first PMA module for adult AKI, and securing its seventh Breakthrough Device Designation for SCD therapy. Operational milestones such as 75% enrollment in the NEUTRALIZE-AKI pivotal trial and the assignment of ICD-10-PCS codes by CMS are presented as catalysts for future growth. The tone is optimistic, with claims of strong adoption, high gross margins above 90%, and broad future applications for SCD therapy. Financial explanations attribute higher R&D expenses to increased clinical activity, while lower G&A costs are credited to reduced personnel and legal expenses. The company does not downplay its net loss or cash position, but positions these as investments in growth.

What the data suggests

Net revenue rose from $0.2 million in Q3 2025 to $0.6 million in Q3 2026, a 247% increase, driven by expanded QUELIMMUNE sales. Gross profit margins remained above 90%, with cost of goods sold at $48 thousand. Research and development expenses nearly doubled to $3.6 million, reflecting heavy investment in the NEUTRALIZE-AKI pivotal trial and SCD development. General and administrative expenses fell to $1.6 million, while other income turned positive at $0.1 million. Despite revenue growth, net loss widened to $4.5 million ($1.03 per share) from $3.5 million ($1.30 per share) a year earlier, as higher R&D spending outpaced sales gains. Cash at September 30, 2026, was $4.0 million, down from $12.0 million at year-end 2025, not including $3.3 million in warrant proceeds received in October. The NEUTRALIZE-AKI trial is 75% enrolled (251 of 339 patients), with completion targeted for mid-2027, indicating that major revenue from adult indications is not imminent. Pediatric clinical data show a 77% survival rate and 87.5% normal kidney function at Day 60, but these are from small cohorts and lack full comparator detail. The company’s financial disclosures are detailed, but clinical claims are less substantiated.

Analysis

The announcement uses positive language to highlight revenue growth (247% YoY to $0.6M) and strong gross margins (>90%), but the company remains deeply loss-making (net loss $4.5M in Q3 2026) and is burning cash, with only $4.0M on hand at quarter-end (plus $3.3M from warrants post-period). While QUELIMMUNE is commercialized for pediatric AKI, the addressable market is ultra-rare and current revenues are modest. The NEUTRALIZE-AKI pivotal trial for adults is only 75% enrolled, with completion not expected until mid-2027, so any material revenue or profit impact from this larger indication is long-term and uncertain. The company is investing heavily in R&D ($3.6M in Q3), and the narrative emphasizes future potential (broader SCD applications, regulatory designations, and possible long-term organ recovery) without near-term earnings visibility. Several claims about clinical outcomes and regulatory progress are not fully substantiated with detailed data or third-party confirmation. The gap between narrative and evidence is moderate: realized pediatric sales are small, while most upside is projected and capital-intensive.

Risk flags

• ●Cash burn is significant, with cash declining from $12.0 million at year-end 2025 to $4.0 million at September 30, 2026, even before factoring in $3.3 million in post-period warrant proceeds. This raises the risk of future dilution or funding shortfalls if revenue growth does not accelerate.
• ●Net losses are widening, reaching $4.5 million in Q3 2026, driven by high R&D expenses for the NEUTRALIZE-AKI trial and SCD development. Sustained losses without near-term profitability increase financial vulnerability.
• ●The NEUTRALIZE-AKI pivotal trial for adult AKI is only 75% enrolled, with completion not expected until mid-2027. Any revenue or approval from this larger market is contingent on successful trial outcomes and regulatory review, introducing substantial execution and clinical risk.
• ●Claims of strong clinical benefit for QUELIMMUNE are based on small pediatric cohorts and lack detailed comparator and statistical data, limiting external validation and increasing uncertainty around broader efficacy.
• ●While the company has secured seven Breakthrough Device Designations and new billing codes, these regulatory milestones do not guarantee FDA approval or commercial success, and the addressable market for current pediatric indications remains small.

Bottom line

SeaStar Medical is showing rapid revenue growth in a niche pediatric market, but its quarterly sales remain modest at $0.6 million and are outweighed by high R&D-driven losses. The company is investing heavily in clinical development, particularly for adult AKI, but any material revenue from this indication is at least 18 months away and subject to clinical and regulatory risk. Cash reserves are low relative to burn rate, making additional capital raises likely before the NEUTRALIZE-AKI trial concludes. While regulatory progress and strong gross margins are positives, the current business is not self-sustaining and most upside is long-dated and speculative. Investors should focus on cash runway, trial progress, and evidence of broader clinical efficacy as key future catalysts. The main takeaway is that while growth is real, the path to profitability and large-scale adoption remains uncertain and capital-intensive.

Announcement summary

(NASDAQ:ICU) SeaStar Medical Holding Corporation reported financial results for the three months ended September 30, 2026, and provided business updates. Eric Schlorff, CEO, stated that QUELIMMUNE therapy adoption in the ultra-rare pediatric AKI market is strong and that the company is building momentum in educating the critical care pediatric healthcare community. Dr. Kevin Chung, CMO, presented statistically significant higher survival in QUELIMMUNE-treated patients at ASN Kidney Week 2026. The NEUTRALIZE-AKI pivotal clinical trial has enrolled nearly 75% of its intended 339 patients, with 251 enrolled to date, and the first module of the premarket approval application has been submitted to the FDA. SeaStar Medical received Breakthrough Device Designation from the FDA for the SCD therapy for hyperinflammation in adult patients with sepsis or a septic condition, marking the seventh such designation for the SCD therapy. The company received dedicated ICD-10-PCS codes from CMS effective October 1, 2026, enabling administrative, billing, and statistical reporting for SCD therapy in AKI patients requiring RRT. Net revenue for Q3 2026 was $0.6 million, up 247% from $0.2 million in Q3 2025, driven by increased sales of QUELIMMUNE. Gross profit margins remained above 90%. Cost of goods sold was $48 thousand in Q3 2026 versus $14 thousand in Q3 2025. Research and development expenses were $3.6 million in Q3 2026 compared to $1.9 million in Q3 2025, primarily due to increased clinical research activities for NEUTRALIZE-AKI, SCD development, and personnel costs. General and administrative expenses were $1.6 million in Q3 2026 versus $1.9 million in Q3 2025, with the decrease attributed to lower personnel, legal, audit, and SEC-related costs, partially offset by higher professional services, director fees, and franchise taxes. Other income (net) was $0.1 million in Q3 2026 compared to other expense of $0.1 million in Q3 2025. Net loss for Q3 2026 was $4.5 million, or $1.03 per share on 4.4 million weighted-average shares outstanding, compared to a net loss of $3.5 million, or $1.30 per share, on 2.7 million weighted-average shares outstanding in Q3 2025. Cash at September 30, 2026, was $4.0 million, not including $3.3 million of gross proceeds from warrant exercises in October 2026, compared to $12.0 million at December 31, 2025. The QUELIMMUNE (SCD-PED) therapy is commercialized for children with AKI and sepsis or a septic condition weighing 10 kilograms or more and aged ≤22 years, approved in February 2024 under a Humanitarian Device Exemption. Data from two clinical trials published in Kidney Medicine showed a 77% survival rate in patients treated with QUELIMMUNE versus standard of care, representing an approximate 50% reduction in loss of life compared to historical data. No dialysis was required for survivors, and 87.5% of survivors had normal kidney function at Day 60 after ICU discharge. The NEUTRALIZE-AKI pivotal trial is evaluating SCD therapy in 339 adults with AKI in the ICU receiving CRRT, with primary and secondary endpoints including 90-day mortality or dialysis dependency, 28-day mortality, ICU-free days, major adverse kidney events at Day 90, and dialysis dependency at one year. The study will also include subgroup analyses for AKI patients with sepsis and acute respiratory distress syndrome. The company will hold a third quarter financial results conference call on November 11, 2026, at 4:30 p.m. ET.

Disagree with this article?